If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster ...

It is nearly eight years since healthcare and biotech investor Sam Isaly abruptly stepped down from OrbiMed, the managers of the Worldwide Healthcare Trust (LSE: WWH). In the 22 years in which he was ...

For years, public debate around U.S. dependence on China has focused on semiconductors, consumer electronics, rare earth minerals and industrial manufacturing. Far less attention has been paid to a ...

Arthur Herman’s op-ed, “America Is the Sole Superpower Again,” (Jan. 15) asserts that China is “sliding into a distant second place” in the battle for economic, military and technological supremacy.

SANA’s thesis rests on hypoimmune islet replacement for T1D. UP421 gives it early human validation, and SC451 is the main scalable follow-on asset. SC451’s planned 2026 IND is the primary catalyst ...

To share your story, or find out how to get involved with CNBC Cures, email CNBC.cures@cnbc.com China is pumping money into its biotech industry, helping launch a new wave of labs and incubators in ...

Why personalized gene editing, genetic resurrections and embryo scoring made our list. Earlier this week, MIT Technology Review published its annual list of Ten Breakthrough Technologies. As always, ...

A run of pharmaceutical mergers and acquisitions is fueling optimism that biotechnology venture capital is poised to rebound from its postpandemic slump. With $223 billion in biotech M&A deals ...

2025 proved a turning point year for the biotech industry, albeit one wrought with contradiction. The post-COVID slump experienced by the industry seemed due to continue, with the sweeping cuts to the ...

Biotech IPOs hit lowest level in over a decade in 2025 Investors focus on biotechs with mature pipelines and positive trial data Lower interest rates and capital inflows expected to boost sector Jan ...

The green shoots suggesting a comeback was in sight for biotech stocks last year have mostly grown into proverbial flowering plants—but one company’s precipitous year-over-year decline in market ...

After failed acquisitions talks with upGrad, Bengaluru-based edtech unicorn Unacademy plans to exit its offline business by converting company operated centres into franchise partnerships. In an ...